BEAM

28.90

3.92% -1.18

Dopo l'orario di chiusura: 28.86 -0.04 -0.14%

Beam Therapeutics Inc (BEAM)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BEAM Giù? Forum Previsione

Precedente Chiudi:

$30.08

Aprire:

$30.67

Volume 24 ore:

2.05M

Relative Volume:

1.04

Capitalizzazione di mercato:

$2.97B

Reddito:

$139.74M

Utile/perdita netta:

$-79.99M

Rapporto P/E:

-28.45

EPS:

-1.0157

Flusso di cassa netto:

$-360.05M

1 W Prestazione:

-5.43%

1M Prestazione:

+17.19%

6M Prestazione:

+25.27%

1 anno Prestazione:

+45.81%

Intervallo 1D:

$28.50

$31.24

Intervallo di 1 settimana:

$28.50

$31.93

Portata 52W:

$15.35

$36.44

Beam Therapeutics Inc Stock (BEAM) Company Profile

Nome

Beam Therapeutics Inc

Settore

Healthcare (1106)

Industria

Biotechnology (615)

Telefono

857-327-8775

Indirizzo

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Dipendente

511

Cinguettio

Prossima data di guadagno

2026-05-05

Ultimi documenti SEC

BEAM's Discussions on Twitter

Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BEAM Beam Therapeutics Inc	28.90	3.09B	139.74M	-79.99M	-360.05M	-1.0157
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-20	Iniziato	Canaccord Genuity	Buy
2025-10-09	Iniziato	Jefferies	Buy
2025-03-28	Aggiornamento	BofA Securities	Neutral → Buy
2025-03-10	Aggiornamento	Scotiabank	Sector Perform → Sector Outperform
2025-01-29	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2024-11-06	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-07-23	Iniziato	H.C. Wainwright	Buy
2024-01-29	Aggiornamento	JP Morgan	Neutral → Overweight
2023-12-15	Downgrade	BofA Securities	Buy → Neutral
2023-12-08	Downgrade	Jefferies	Buy → Hold
2023-10-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-10-20	Downgrade	Leerink Partners	Outperform → Market Perform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2023-02-01	Iniziato	Cantor Fitzgerald	Overweight
2022-12-20	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2022-12-13	Iniziato	Citigroup	Buy
2022-06-17	Iniziato	BMO Capital Markets	Market Perform
2022-04-28	Iniziato	Credit Suisse	Neutral
2022-01-05	Iniziato	Guggenheim	Buy
2021-10-19	Iniziato	SVB Leerink	Outperform
2021-09-24	Ripresa	Stifel	Buy
2021-09-10	Iniziato	BofA Securities	Buy
2021-05-11	Iniziato	Redburn	Buy
2021-05-04	Iniziato	RBC Capital Mkts	Sector Perform
2021-03-01	Downgrade	Barclays	Overweight → Equal Weight
2021-02-16	Iniziato	Wells Fargo	Overweight
2021-01-29	Downgrade	JP Morgan	Overweight → Neutral
2021-01-06	Iniziato	Stifel	Hold
2020-08-05	Iniziato	William Blair	Outperform
2020-03-02	Iniziato	Barclays	Overweight
2020-03-02	Iniziato	JP Morgan	Overweight
2020-03-02	Iniziato	Jefferies	Buy
2020-03-02	Iniziato	Wedbush	Outperform

Mostra tutto

Beam Therapeutics Inc Borsa (BEAM) Ultime notizie

May 04, 2026

Why Beam Therapeutics (BEAM) Is Up 5.3% After TIME100 Spotlight and Vanguard Stake Disclosure - Yahoo Finance

May 04, 2026

Prime Editing and CRISPR Market is expected to Hit US$ 11.46 - openPR.com

May 04, 2026

May 03, 2026

Beam Therapeutics’ TIME Honor Puts Base Editing And Valuation In Focus - Yahoo Finance

May 03, 2026

May 02, 2026

Beam Therapeutics Advances Base Editing Platform with Strong Clinical Data - HarianBasis.co

May 02, 2026

Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now? - Insider Monkey

May 02, 2026

Apr 30, 2026

14 Stocks on Jim Cramer’s Radar: Nokia, Cameco, and AI Stocks’ Dip - Insider Monkey

Apr 30, 2026

Jim Cramer Believes Beam Therapeutics Is a “Speculative Situation” - Insider Monkey

Apr 30, 2026

Price-Driven Insight from (BEAM) for Rule-Based Strategy - Stock Traders Daily

Apr 30, 2026

MSN Money - MSN

Apr 30, 2026

Apr 29, 2026

Vanguard Capital Mgmt (NASDAQ: BEAM) reports 5.02% ownership stake - Stock Titan

Apr 29, 2026

H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo

Apr 29, 2026

Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study - Insider Monkey

Apr 29, 2026

Concurrent Investment Advisors LLC Invests $2.13 Million in Beam Therapeutics Inc. $BEAM - MarketBeat

Apr 29, 2026

Apr 28, 2026

10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey

Apr 28, 2026

Beam Therapeutics (BEAM) Projected to Post Earnings on Tuesday - MarketBeat

Apr 28, 2026

Apr 27, 2026

Beam Therapeutics shows rising relative strength; still shy of key benchmark - MSN

Apr 27, 2026

Beam Therapeutics (NASDAQ:BEAM) Trading Up 8.4%What's Next? - MarketBeat

Apr 27, 2026

Beam Therapeutics (BEAM) Shares Surge 10.7% on Positive Market M - GuruFocus

Apr 27, 2026

S&P 500 Holds Near Highs Despite Oil Shock and Weak Breadth Data - Investing.com

Apr 27, 2026

Beam Therapeutics (BEAM) Shares Rise Over 10% Amid Positive Mark - GuruFocus

Apr 27, 2026

XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday - Benzinga

Apr 27, 2026

3 Biotech Stocks That Could Benefit from the Patent Cliff - MarketBeat

Apr 27, 2026

Beam Therapeutics (BEAM) H.C. Wainwright 27th Annual Global Investment Conference summary - Quartr

Apr 27, 2026

Beam Therapeutics (BEAM) Jefferies 2024 Global Healthcare Conference Summary - Quartr

Apr 27, 2026

Beam Therapeutics (BEAM) Jefferies London Healthcare Conference 2024 Summary - Quartr

Apr 27, 2026

Apr 26, 2026